REMARKS

This is in response to the Official Action of October 31, 2005.

The allowance of claims 1-3, 6-12, 22 and 23 is acknowledged with appreciation.

Claims 13 and 24 stand rejected under the first paragraph of 35 USC 112, it being stated that the specification is not enabling for skin cancer, central nervous system cancer, and cancer in the general sense. Since the compound claims would cover any use of the claimed compounds, these claims have been amended to direct them to the cancers for which enablement is acknowledged in the official action (by incorporation of the pertinent portions of claims 14 and 25). Claims 14 and 25 have been cancelled as redundant. Accordingly, it is respectfully submitted that this rejection may be withdrawn. Accordingly, it is submitted that claims 13 and 24, and those claims dependent thereon, should now be allowed.

It is respectfully submitted that this application is in condition for allowance, which action is respectfully requested.

Myers Bigel Sibley & Sajovec, P.A.

P. O. Box 37428

Raleigh, North Carolina 27627 Telephone: (919) 854-1400

Facsimile: (919) 854-1401

Respectfully submitted.

Kenneth D. Sibley

Registration No. 31,665

Doc. 491824